OPKO Completes Acquisition of Inspiro Medical Ltd.

MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE:OPK)
announced that it has completed the acquisition of Inspiro Medical Ltd.
(“Inspiro”), an Israeli medical device company developing a new platform
to deliver small molecule drugs such as corticosteroids and beta
agonists or larger molecules to treat respiratory diseases. Inspiro’s
Inspiromatic™ is a “smart” easy-to-use dry powder inhaler with several
advantages over existing devices.

In a recently completed, First In Man double blinded clinical study
conducted in 30 asthmatic children comparing Inspiromatic™ to a market
leading dry powder inhaler, Inspiromatic™ demonstrated superior
pulmonary delivery of the active drug.

Inspiromatic™ offers improved drug deposition to the lower airways of
patients and real time data for patient compliance monitoring. The
device has an internal microcontroller and flow sensor that controls the
delivery of the medication and, using micro-pump technology, dispenses
the drug particles at the right speed without the need for forceful
inhalation. It also provides instant feedback to the patient with a
green or red flasher light to indicate proper inhalation and a beeper
after the dose has been delivered. For physicians, Inspiromatic™
provides a built-in logger that stores patient use data for easy access
and transmission by electronic devices such as smart phones.

OPKO is a multinational biopharmaceutical and diagnostics company that
seeks to establish industry leading positions in large, rapidly growing
markets by leveraging its discovery, development and commercialization
expertise and novel and proprietary technologies.

OPKO Health, Inc.Steven D. Rubin or Adam Logal, 305-575-4100

Source: OPKO Health, Inc.